Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: Expression of CD35 and CD59 in acute leukemia patients (both ALL and AML) compared to healthy controls. CD35 and CD59 mRNA expression levels were measured using qRT-PCR in acute leukemia patients, normalized to the housekeeping β-actin genes, and results were compared to CD35 and CD59 mRNA expression level in healthy controls

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, Quantitative RT-PCR

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: Expression of CD35 and CD59 in ALL and AML compared to healthy controls. CD35 and CD59 mRNA expression levels were measured using qRT-PCR in acute leukemia patients, normalized to the housekeeping β-actin genes, and results were compared to both CD35 and CD59 mRNA expression level in healthy controls

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, Quantitative RT-PCR

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: CD35 and CD59 mRNA expression levels based on gender differences in AML patients. CD35 and CD59 mRNA expression levels were measured using qRT-PCR in female and male AML patients, normalized to the housekeeping β-actin genes, and results were compared to both of CD35 and CD59 mRNA expression level in healthy controls

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, Quantitative RT-PCR

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: CD35 and CD59 mRNA expression levels based on gender differences in ALL patients. CD35 and CD59 mRNA expression levels were measured using qRT-PCR in ALL males and females, normalized to the housekeeping β-actin genes, and results were compared to both of CD35 and CD59 mRNA expression levels in healthy controls

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, Quantitative RT-PCR

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: Percentage of CD35 and CD59 expression in acute leukaemia patients. FACS charts showed that expression of CD35 in leukemic patients was reduced by 76.1% when compared to healthy samples, however CD59 expression increased by 20%. *p < 0.05; **p < 0.01, ***p < 0.001

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: CD59 expression levels on cell surfaces using FACS. Cells from blood samples of acute leukemia patients and healthy controls were isolated and analyzed for CD59 expression using flow cytometry (FACS). A and B show that 90.6% of cells from acute leukemia patients expressed CD59, as indicated by their position in the D4 quadrant

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, Isolation, Flow Cytometry

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: CD59 expression levels on cell surfaces using FACS. Cells from blood samples of acute leukemia patients and healthy controls were isolated and analyzed for CD59 expression using flow cytometry (FACS). A and B show that 69.2% of cells from healthy controls expressed CD59, as indicated by their position in the D4 quadrant

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, Isolation, Flow Cytometry

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: Determination of shRNA-mediated knockdown of CD35 and CD59 mCRP expression on HSB-2 cells compared to untransfected controls. Reducing CD35 gene expression in transfected cells decreased CD35 expression by 59% (p < 0.0001). Similarly, reducing CD59 gene expression led to a 98.95% decrease in CD59 expression levels (p < 0.001)

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: shRNA, Knockdown, Expressing, Gene Expression, Transfection

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: CD59 expression on CD59 shRNA untransfected cells. Cells were analyzed for CD59 expression by flow cytometry. Data were obtained from representative experiment samples of a CD59 un-transfected cells. Flow cytometry charts showed an average of CD59 expression level of 4.75% on untransfected cells

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, shRNA, Flow Cytometry, Transfection

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: CD59 expression on CD59 shRNA transfected cells. Cells were analyzed for CD59 expression by flow cytometry. Data were obtained from representative experiment of CD59 transfected cells. Flow cytometry charts showed an average of CD59 expression level of 0.05% on cells transfected

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Expressing, shRNA, Transfection, Flow Cytometry

Journal: Discover Oncology

Article Title: Altered expression of complement regulatory proteins CD35 and CD59 in acute lymphoblastic and acute myeloblastic leukemia suggests a context-based pattern

doi: 10.1007/s12672-026-04818-3

Figure Lengend Snippet: Acute Lymphoblastic Leukaemia cells viability after silencing of CD35 and CD59 mCRPs. The viability of cells transfected with plasmids targeting CD35 and CD59 was compared to untreated cells. Cell viability was measured using the MTT assay in the presence of normal human serum as a complement source. Statistic'ally significant differences were observed between the groups (*p < 0.05; **p < 0.01, ***p < 0.0011)

Article Snippet: The datasets analysed during the current study are available in the following repositories: - CD59 gene and protein - NCBI Gene ID: 966 - OMIM (MIM): 107271 - Ensembl: ENSG00000085063 - CR1 (CD35) gene and protein - NCBI Gene ID: 1378 - OMIM (MIM): 120620 - Ensembl: ENSG00000203710 Gene expression analyses were performed using commercially available TaqMan Gene Expression Assays: - CD59 TaqMan Assay (Hs00174141_m1) - Forward primer: 5′-TGCAATTTCAACGACGTCACA-3′ - Reverse primer: 5′-GAAATGGAGTCACCAGCAGAAGA-3′ - CD35 (CR1) TaqMan Assay (Hs00559348_m1) - Forward primer: 5′-TAGGTGTCAGCCTGGCTTTGTC-3′ - Reverse primer: 5′-GACATCTGGAGGTGGCTGACAT-3′ Gene silencing experiments were conducted using commercially available short hairpin interfering RNA constructs: - CD59 shRNA (sc-37249-SH) - Target sequence: 5′-TGAGCTAACGTACTACTACTGC-3′ - CD35 (CR1) shRNA (sc-29994-SH) - Target sequence: 5′-GGACATCAAGTGGCTAAAT-3′ All reagents are commercially available from Thermo Fisher Scientific and Santa Cruz Biotechnology.

Techniques: Transfection, MTT Assay